Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.670 | 0.0400 | ||||
REV | 14.060M | 16.513M | 2.453M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KYMR | Kymera Therapeutics | 0% | 845M |
VALN | Valneva | 0% | 880.6M |
COGT | Cogent Biosciences | 0% | 852.1M |
AMAM | Ambrx Biopharma | 0% | 666M |
REPL | Replimune Group | 0% | 952.8M |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
There is no dividend information for Kymera Therapeutics.
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.670 | 0.0400 | ||||
REV | 14.060M | 16.513M | 2.453M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KYMR | Kymera Therapeutics | 0% | 845M |
VALN | Valneva | 0% | 880.6M |
COGT | Cogent Biosciences | 0% | 852.1M |
AMAM | Ambrx Biopharma | 0% | 666M |
REPL | Replimune Group | 0% | 952.8M |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
There is no dividend information for Kymera Therapeutics.
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.670 | 0.0400 | ||||
REV | 14.060M | 16.513M | 2.453M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KYMR | Kymera Therapeutics | 0% | 845M |
VALN | Valneva | 0% | 880.6M |
COGT | Cogent Biosciences | 0% | 852.1M |
AMAM | Ambrx Biopharma | 0% | 666M |
REPL | Replimune Group | 0% | 952.8M |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
There is no dividend information for Kymera Therapeutics.
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.670 | 0.0400 | ||||
REV | 14.060M | 16.513M | 2.453M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KYMR | Kymera Therapeutics | 0% | 845M |
VALN | Valneva | 0% | 880.6M |
COGT | Cogent Biosciences | 0% | 852.1M |
AMAM | Ambrx Biopharma | 0% | 666M |
REPL | Replimune Group | 0% | 952.8M |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
There is no dividend information for Kymera Therapeutics.
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.670 | 0.0400 | ||||
REV | 14.060M | 16.513M | 2.453M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KYMR | Kymera Therapeutics | 0% | 845M |
VALN | Valneva | 0% | 880.6M |
COGT | Cogent Biosciences | 0% | 852.1M |
AMAM | Ambrx Biopharma | 0% | 666M |
REPL | Replimune Group | 0% | 952.8M |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
There is no dividend information for Kymera Therapeutics.
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.670 | 0.0400 | ||||
REV | 14.060M | 16.513M | 2.453M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KYMR | Kymera Therapeutics | 0% | 845M |
VALN | Valneva | 0% | 880.6M |
COGT | Cogent Biosciences | 0% | 852.1M |
AMAM | Ambrx Biopharma | 0% | 666M |
REPL | Replimune Group | 0% | 952.8M |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
There is no dividend information for Kymera Therapeutics.
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.670 | 0.0400 | ||||
REV | 14.060M | 16.513M | 2.453M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KYMR | Kymera Therapeutics | 0% | 845M |
VALN | Valneva | 0% | 880.6M |
COGT | Cogent Biosciences | 0% | 852.1M |
AMAM | Ambrx Biopharma | 0% | 666M |
REPL | Replimune Group | 0% | 952.8M |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
There is no dividend information for Kymera Therapeutics.
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.670 | 0.0400 | ||||
REV | 14.060M | 16.513M | 2.453M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KYMR | Kymera Therapeutics | 0% | 845M |
VALN | Valneva | 0% | 880.6M |
COGT | Cogent Biosciences | 0% | 852.1M |
AMAM | Ambrx Biopharma | 0% | 666M |
REPL | Replimune Group | 0% | 952.8M |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
There is no dividend information for Kymera Therapeutics.
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
Day Range- - - | 52 Wk Range14.965 - 39.850 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.670 | 0.0400 | ||||
REV | 14.060M | 16.513M | 2.453M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KYMR | Kymera Therapeutics | 0% | 845M |
VALN | Valneva | 0% | 880.6M |
COGT | Cogent Biosciences | 0% | 852.1M |
AMAM | Ambrx Biopharma | 0% | 666M |
REPL | Replimune Group | 0% | 952.8M |
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
There is no dividend information for Kymera Therapeutics.
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.